BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 21430363)

  • 1. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
    Daniëls V; Baekelandt V; Taymans JM
    Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene].
    Pchelina SN; emel'ianov AK; Usenko TS
    Mol Biol (Mosk); 2014; 48(1):3-14. PubMed ID: 25842821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting leucine-rich repeat kinase 2 in Parkinson's disease.
    Chan SL; Angeles DC; Tan EK
    Expert Opin Ther Targets; 2013 Dec; 17(12):1471-82. PubMed ID: 24206363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 and vesicle trafficking.
    Sanna G; Del Giudice MG; Crosio C; Iaccarino C
    Biochem Soc Trans; 2012 Oct; 40(5):1117-22. PubMed ID: 22988875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease.
    Botta-Orfila T; Tolosa E; Gelpi E; Sànchez-Pla A; Martí MJ; Valldeoriola F; Fernández M; Carmona F; Ezquerra M
    Neurobiol Dis; 2012 Jan; 45(1):462-8. PubMed ID: 21946334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
    Lu YW; Tan EK
    J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cell Biology of LRRK2 in Parkinson's Disease.
    Usmani A; Shavarebi F; Hiniker A
    Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33526455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.
    Drolet RE; Sanders JM; Kern JT
    J Neurogenet; 2011 Dec; 25(4):140-51. PubMed ID: 22077787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse models for LRRK2 Parkinson's disease.
    Xu Q; Shenoy S; Li C
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.
    Bravo-San Pedro JM; Gómez-Sánchez R; Niso-Santano M; Pizarro-Estrella E; González-Polo RA; Fuentes JM
    Biochem Soc Trans; 2012 Oct; 40(5):1129-33. PubMed ID: 22988877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
    Gandhi PN; Chen SG; Wilson-Delfosse AL
    J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease.
    Yescas P; López M; Monroy N; Boll MC; Rodríguez-Violante M; Rodríguez U; Ochoa A; Alonso ME
    Neurosci Lett; 2010 Nov; 485(2):79-82. PubMed ID: 20727385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease.
    Mutez E; Nkiliza A; Belarbi K; de Broucker A; Vanbesien-Mailliot C; Bleuse S; Duflot A; Comptdaer T; Semaille P; Blervaque R; Hot D; Leprêtre F; Figeac M; Destée A; Chartier-Harlin MC
    Neurobiol Dis; 2014 Mar; 63():165-70. PubMed ID: 24269915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2.
    Belluzzi E; Greggio E; Piccoli G
    Biochem Soc Trans; 2012 Oct; 40(5):1111-6. PubMed ID: 22988874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.